Drugs / XKH001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07070297 | Dec 2023 → Oct 2024 | asthma | Zhejiang Kanova Biopharmaceutical Co., LTD | Completed | No outcome recorded |
| Comparator or background therapy4 trials | ||||||
| Phase 1 | NCT05128409 Comparator | Mar 2023 → Oct 2024 | — | Beijing Kanova Biopharmaceutical Co., LTD | Unknown | No outcome recorded |
| Phase 1/2 | NCT05991661 Comparator | May 2023 → Feb 2024 | asthma | Beijing Kanova Biopharmaceutical Co., LTD | Completed | No outcome recorded |
| Phase 2 | NCT07519499 Comparator | Apr 2026 → Dec 2027 expected | chronic obstructive pulmonary disease | Zhejiang Kanova Biopharmaceutical Co., LTD | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07054736 Comparator | Aug → Oct 2025 overdue | atopic eczema | Zhejiang Kanova Biopharmaceutical Co., LTD | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XKH001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07070297 ↗ |
| Action | Inhibit | “XKH001 specifically blocks interleukin-25 from binding to its receptors.” NCT05128409 ↗ |
| Modality | Monoclonal antibody | “XKH001is a recombinant humanized monoclonal IgG1 antibody for subcutaneous injection.” NCT05128409 ↗ |
| Route | Subcutaneous | “subcutaneous injection” NCT05128409 ↗ |
| Target | IL25 | “XKH001 is a recombinant humanized IgG1 monoclonal antibody against IL-25 for the treatment of type 2 inflammatory diseases.” PMID 39815604 ↗ Jan 2025 |